HBP:CC - Helix Biopharma Corp. Announces Board & Management Changes
(TheNewswire)
Toronto, O N – TheNewswire - December 8, 2022 - HelixBioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), aclinical-stage biopharmaceutical company developing unique therapiesin the field of immuno-oncology, based on its proprietarytechnological platform DOS47, today announced changes in its board ofdirectors (the "Board") and management.
The Company is pleased to announce that Mr. Jacek Antashas been appointed as the Company’s CEO to replace Mr. Artur Gaborwith immediate effect. Mr. Gabor has resigned as the CEO and adirector of the Board of the Company. Mr. Antas has been on the Boardof the Company since April 2022. He has more than 25 years ofexperience in the financial services industry holding variouspositions in sales and consulting. Mr. Antas obtained a master’s degree from the Warsaw School of Economics andhas served as a board member of variouscompanies throughout his career.
The Company is also pleased to announce the appointmentof Ms. Malgorzata Irena Laube on the Board, with immediate effect. Ms.Laube has over 19 years of experience in nuclear medicine. In her lastrole with Alberta Health Services, she was the Department Supervisor,Nuclear Medicine at Royal Alexandra Hospital. Ms. Laube obtained a MScdegree in Environmental Engineering from the Warsaw University ofTechnology. Ms. Laube is based in Edmonton, Alberta, Canada.
“On behalf of Helix, I would like to thank Mr. Gaborfor his service as the CEO and welcome Mr. Antas to the new role”said Mr . Jerzy Leszczyn?ski, Chair of the Audit Committee. “We are also delighted that Ms.Laube has agreed to join the Board of the Company. The Board andManagement team look forward to working with Mr. Antas and Ms. Laubein their new roles . ” continued Mr. Leszczyn?ski .
Helix BioPharma Corp. is a clinical-stagebiopharmaceutical company developing unique therapies in the field ofimmune-oncology for the prevention and treatment of cancer based onour proprietary technological platform DOS47. Helix is listed on the TSX under the symbol “HBP”.
For more information, please contact:
Helix BioPharma Corp.
Suite 2704, 401 Bay Street Toronto, Ontario, M5H 2Y4
Tel: 905-841-2300
Namrata Malhotra, CorporateSecretary
Forward-LookingStatements and Risks and Uncertainties
This news release containsforward-looking statements and information (collectively,“forward-looking statements”) within the meaning of applicableCanadian securities laws. Forward-looking statements are statementsand information that are not historical facts but instead includefinancial projections and estimates, statements regarding plans,goals, objectives, intentions and expectations with respect to theCompany’s future business, operations, research and development,including the Company’s activities relating to DOS47 . Forward-looking statements can further be identified by the use offorward-looking terminology such as “ongoing”, “estimates”,“expects”, or the negative thereof or any other variations thereonor comparable terminology referring to future events or results, orthat events or conditions “will”, “may”, “could”, or“should” occur or be achieved, or comparable terminology referringto future events or results.
Forward-looking statements arestatements about the future and are inherently uncertain and arenecessarily based upon a number of estimates and assumptions that arealso uncertain. Although the Company believes that the expectationsreflected in such forward- looking statements are reasonable, such statementsinvolve risks and uncertainties, and undue reliance should not beplaced on such statements. Forward-looking statements, includingfinancial outlooks, are intended to provide information aboutmanagement’s current plans and expectations regarding futureoperations, including without limitation, future financingrequirements, and may not be appropriate for other purposes. Certainmaterial factors, estimates or assumptions have been applied in makingforward-looking statements in this news release.
The Company’s actual results coulddiffer materially from those anticipated in the forward-lookingstatements contained in this news release as a result of numerousknown and unknown risks and uncertainties, including withoutlimitation; the risk that the Company’s assumptions may prove to beincorrect; the risk that additional financing may not be obtainable ina timely manner, or at all, and that clinical trials may not commenceor complete within anticipated timelines or the anticipated budget ormay fail; third party suppliers of necessary services or of drugproduct and other materials may fail to perform or be unwilling orunable to supply the Company, which could cause delay or cancellationof the Company’s research and development activities; necessaryregulatory approvals may not be granted or may be withdrawn; theCompany may not be able to secure necessary strategic partner support;general economic conditions, intellectual property and insurancerisks; changes in business strategy or plans; and other risks anduncertainties referred to elsewhere in this news release, any of whichcould cause actual results to vary materially from current results orthe Company’s anticipated future results. Certain of these risks anduncertainties, and others affecting the Company, are more fullydescribed in the Company’s annual management’s discussion andanalysis for the year ended July 31, 2022 under the heading “Risksand Uncertainties” and Helix’s Annual Information Form, inparticular under the headings “Forward-looking Statements” and“Risk Factors”, and other reports filed under the Company’sprofile on SEDAR at www.sedar.com from time to time.Forward-looking statements and information are based on the beliefs,assumptions, opinions and expectations of Helix’s management on thedate of this new release, and the Company does not assume anyobligation to update any forward-looking statement or informationshould those beliefs, assumptions, opinions or expectations, or othercircumstances change, except as required.
Copyright (c) 2022 TheNewswire - All rights reserved.